Collectively, these data identify brigatinib as a direct and potent inhibitor of multiple kinases, including FAK1 (PTK2) and FAK2 (PTK2B), and novel targets, GAK and TNK2, in both arachnoid and schwannoma cells. The gene discussed is PTK2B; the disease is schwannoma.